Naringerin as candidate drug against SARS-CoV-2: The role for TPC2 genomic variants in COVID-19.

Emilio Di Maria, Paolo Martini, Massimo Gennarelli

Erratum issuedOpen access · greenAbstract readLetterComment

In one paragraph

Article in Pharmacological research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

0.1field-weighted citation impact, top 51% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

Identification of key molecules in COVID-19 patients significantly correlated with clinical outcomes by analyzing transcriptomic data.Frontiers in immunology · 2022
Article

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Emilio Di MariaDept. of Health Sciences, University of Genoa, Italy; Unit of Medical Genetics, Galliera Hospital, Genoa, Italy. Electronic address: emilio.dimaria@unige.it.

Paolo MartiniDepartment of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.

Massimo GennarelliDepartment of Molecular and Translational Medicine, University of Brescia, Brescia, Italy; Genetics Unit, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.

Centro San Giovanni di Dio Fatebenefratelli · ITEnte Ospedaliero Ospedali Galliera · ITUniversity of Brescia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19Pharmaceutical PreparationsFlavanonesGenomicsHumansSARS-CoV-2FlavanonesnaringeninPharmaceutical Preparations

Identifiers

PMID33359911

DOI10.1016/j.phrs.2020.105402

PMCPMC7834538

OpenAlexW3114999734

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.